Semaglutide: How It Works, Uses, Benefits, Side Effects and Safety Guide

Semaglutide has become one of the most widely discussed medicines in modern diabetes and obesity management. It belongs to a class of medicines known as GLP-1 receptor agonists and has been developed in both injectable and oral forms.

Many people first heard about semaglutide because of its association with weight loss. However, semaglutide was originally developed as a medicine for type 2 diabetes, and its effects extend beyond body weight. Depending on the specific product, formulation, dose, and country, semaglutide is used for different approved indications.

In the European Union, for example, Ozempic is authorized for adults with inadequately controlled type 2 diabetes, Rybelsus is an oral semaglutide product for type 2 diabetes, and Wegovy is authorized for weight management in eligible adults and certain adolescents. Product indications and formulations can differ between jurisdictions, so the current local product information should always be checked.

This article explains semaglutide in simple, practical language, including how it works, where it is used, potential benefits, common adverse effects, important precautions, and why proper medical supervision matters.

Medical information notice: This article is for general educational purposes and is not a substitute for diagnosis, prescribing, or individualized medical advice. Semaglutide should be used according to an approved product label and under appropriate healthcare supervision.

What Is Semaglutide?

Semaglutide is a long-acting GLP-1 receptor agonist. GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone involved in the regulation of blood glucose, appetite, and food intake.

Semaglutide is designed to mimic some of the actions of natural GLP-1, but it remains active in the body much longer than the naturally occurring hormone.

It is available in different pharmaceutical formulations. Depending on the market and product, semaglutide may be administered as:

• A once-weekly subcutaneous injection
• A once-daily oral tablet

Examples of marketed semaglutide products include Ozempic, Wegovy, and Rybelsus, although the exact approved indications and formulations vary by jurisdiction.

How Does Semaglutide Work?

To understand semaglutide, it helps to understand what happens after eating.

When food enters the digestive system, the body releases hormones including GLP-1. GLP-1 contributes to several physiological processes.

Semaglutide activates GLP-1 receptors and produces effects that can help control blood glucose and appetite.

1. It Helps Increase Insulin Secretion When Glucose Is Elevated

Semaglutide increases glucose-dependent insulin secretion from pancreatic beta cells.

In simple terms, when blood glucose rises, semaglutide helps the body release more insulin.

This contributes to improved blood glucose control in people with type 2 diabetes. EMA describes semaglutide's action in Rybelsus as increasing insulin release from the pancreas in response to food.

2. It Reduces Glucagon Secretion

Glucagon is a hormone that can increase blood glucose.

GLP-1 receptor activation can reduce inappropriate glucagon secretion, helping support glucose regulation.

3. It Slows Gastric Emptying

Semaglutide can delay the movement of food from the stomach into the intestine.

This can contribute to:

• Earlier fullness
• Reduced appetite
• Lower food intake

4. It Influences Appetite

Semaglutide acts on pathways involved in appetite regulation. People receiving semaglutide may experience less hunger and fewer food cravings.

The EMA describes Wegovy as increasing feelings of fullness while reducing hunger, food intake, and cravings.

This combination of effects explains why semaglutide can be useful for both glycemic management and, in appropriate patients, weight management.

ALSO READ: The Pharmacist

Semaglutide for Type 2 Diabetes

One of the major uses of semaglutide is the treatment of type 2 diabetes.

In type 2 diabetes, the body may become resistant to insulin and may not produce enough insulin to maintain normal blood glucose.

Semaglutide can improve glucose control through its effects on insulin, glucagon, appetite, and food intake.

For example, Rybelsus is authorized in the EU for adults with insufficiently controlled type 2 diabetes, together with diet and exercise. It can be used alone when metformin is inappropriate because of intolerance or contraindications, or in combination with other diabetes medicines.

Semaglutide is therefore not simply a "weight-loss medicine." It is an important medicine within the broader treatment landscape for type 2 diabetes.

Semaglutide for Weight Management

Semaglutide has also become particularly important in obesity medicine.

Wegovy is authorized in the EU, together with a reduced-calorie diet and increased physical activity, for weight management in eligible adults with obesity or overweight accompanied by at least one weight-related health problem. It is also authorized for certain adolescents aged 12 years and older with obesity under specified criteria.

The reason semaglutide can produce substantial weight reduction is primarily related to reduced energy intake.

A person may feel full after eating a smaller amount and may experience reduced hunger or cravings.

This is important because obesity is a chronic disease, and maintaining weight reduction can be difficult through lifestyle intervention alone for many patients.

How Much Weight Can Semaglutide Help People Lose?

Results vary considerably between individuals.

In the landmark STEP 1 randomized clinical trial, adults with obesity or overweight plus a weight-related condition, but without diabetes, received once-weekly semaglutide 2.4 mg or placebo together with lifestyle intervention for 68 weeks.

The mean body-weight change was approximately 14.9% with semaglutide compared with 2.4% with placebo.

About 86.4% of participants receiving semaglutide achieved at least 5% weight loss, compared with 31.5% receiving placebo.

These results should not be interpreted as a guarantee that every person will lose 15% of their body weight. Individual responses depend on factors such as medical history, adherence, diet, physical activity, treatment duration, and tolerance.

ALSO READ: PEBC Exams Information to Get Pharmacist License for Foreign Pharmacy Graduates in Canada

A Simple Example of How Semaglutide May Affect Appetite

Imagine a person who normally eats a large lunch and still feels hungry soon afterward.

After treatment with an appropriate semaglutide product, that person may experience stronger feelings of fullness. They might naturally eat a smaller portion and feel satisfied for longer.

Over time, repeated reductions in calorie intake can contribute to weight loss.

This is different from a stimulant that simply "burns fat." Semaglutide primarily changes appetite and metabolic signaling, resulting in reduced energy intake.

How Is Semaglutide Taken?

The administration schedule depends on the product.

Some semaglutide products are injected once weekly, while oral semaglutide products are taken once daily.

For injectable products, treatment is generally started at a lower dose and gradually increased. The gradual increase is intended to improve gastrointestinal tolerability.

For example, clinical trials of once-weekly semaglutide for obesity used dose escalation over several weeks before reaching the target dose.

Patients should follow the exact titration schedule prescribed for their product. Different semaglutide products are not interchangeable simply because they contain the same active ingredient.

Common Side Effects of Semaglutide

The most frequently reported adverse effects are related to the gastrointestinal system.

Common reactions can include:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal discomfort
• Reduced appetite

These symptoms may be more noticeable when treatment is initiated or when the dose is increased.

One reason dose escalation is commonly used is to allow the body to gradually adapt to the medicine.

For many patients, gastrointestinal symptoms become less troublesome over time, but persistent or severe symptoms should be discussed with a healthcare professional.

Important Serious Risks and Precautions

Although semaglutide can be effective, it is not appropriate for everyone.

Pancreatitis

Acute pancreatitis is an important potential adverse event associated with GLP-1 receptor agonist therapy.

Symptoms that may require urgent medical evaluation include severe and persistent abdominal pain, sometimes radiating to the back, with or without vomiting. Product labeling instructs patients to promptly seek medical advice if pancreatitis is suspected.

Gallbladder Disease

Gallstones and inflammation of the gallbladder can occur.

The risk may also be influenced by substantial or rapid weight loss. FDA labeling for Wegovy notes increased occurrence of gallbladder disease in clinical trials.

Hypoglycemia

Semaglutide itself generally has a lower risk of hypoglycemia than some glucose-lowering medicines when used alone. However, the risk can increase when it is combined with certain other diabetes treatments.

Patients with diabetes should therefore follow their prescribed regimen carefully.

Dehydration and Kidney Problems

Vomiting or diarrhea can result in significant fluid loss.

In susceptible patients, dehydration may contribute to kidney problems. Adequate monitoring is important, particularly when significant gastrointestinal adverse effects occur.

Thyroid Tumor Warning

Some semaglutide prescribing information contains an important warning concerning thyroid C-cell tumors.

In animal studies, semaglutide caused thyroid C-cell tumors. It is not known whether this finding applies to humans. FDA-approved semaglutide labeling states that semaglutide products are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

This is an important example of why semaglutide should not be viewed as a casual weight-loss product.

A healthcare professional needs to assess a patient's medical history before treatment.

ALSO READ: Steps to Becoming a Licensed Pharmacist in the US: A Comprehensive Guide

What About Semaglutide During Pregnancy?

Weight-loss treatment is generally not appropriate during pregnancy.

People who are pregnant, planning pregnancy, or breastfeeding should discuss semaglutide with their healthcare provider because recommendations can differ depending on the specific product, indication, and clinical circumstances.

Patients should not stop or continue prescription medicines based only on information from an internet article.

Semaglutide and Other Medicines

Semaglutide may be used together with other medicines, but interactions and combined effects need to be evaluated.

For patients with diabetes, particular attention may be required when semaglutide is combined with medicines that can independently cause hypoglycemia.

Because semaglutide also affects gastric emptying, healthcare professionals may consider whether changes in absorption could be clinically relevant for certain orally administered medicines.

The patient's complete medication list should therefore be reviewed before treatment.

Semaglutide, Ozempic, Wegovy and Rybelsus: What Is the Difference?

These names can be confusing because they contain the same active ingredient but are used in different approved contexts.

Product	Active Ingredient	Formulation	Main Approved Use*
Ozempic	Semaglutide	Injection	Type 2 diabetes
Wegovy	Semaglutide	Injection / market-dependent formulation	Weight management
Rybelsus	Semaglutide	Oral tablet	Type 2 diabetes

*Approved uses and formulations vary by jurisdiction and may change as regulatory decisions are updated. Current local product information should always be consulted.

The existence of different brand names does not mean that patients should switch between products independently.

Oral Semaglutide vs Injectable Semaglutide

The oral form is particularly interesting because peptide medicines are generally challenging to administer orally.

Oral semaglutide uses a formulation technology that facilitates absorption through the gastrointestinal tract. EMA's product information identifies SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) as part of the oral formulation to facilitate semaglutide absorption.

Oral and injectable products also have different administration instructions.

For example, EMA states that Rybelsus tablets are taken once daily according to specific fasting and administration instructions.

Therefore, patients should not assume that an oral tablet can be taken in exactly the same way as a weekly injection.

What Happens After Stopping Semaglutide?

One common misconception is that semaglutide permanently "resets" the body's appetite.

The effect does not necessarily continue after treatment is stopped.

Because semaglutide's appetite and metabolic effects depend on continued exposure to the medicine, some people may experience increased appetite and weight regain after discontinuation.

This is one reason weight management should be considered a long-term medical issue rather than simply a short course of treatment.

The decision to continue, adjust, or stop therapy should be made with a healthcare professional.

Why People Should Be Careful With Compounded Semaglutide

The popularity of semaglutide has led to extensive use and marketing of compounded products in some markets.

This creates an important safety issue.

FDA has reported dosing errors involving compounded injectable semaglutide, including cases caused by confusion between milligrams, milliliters, and syringe units. Some reported adverse events were serious and required hospitalization.

FDA also states that compounded drugs do not undergo the same FDA premarket review for safety, effectiveness, and quality as FDA-approved medicines.

Another important issue is that compounded products can come in different concentrations.

A patient who receives an incorrect concentration or incorrectly converts a prescribed dose into syringe units could potentially administer substantially more medicine than intended.

This is why patients should never calculate or change a semaglutide dose independently.

References

1. European Medicines Agency. Wegovy (semaglutide) — European Public Assessment Report and Product Information. Updated August 2026.
2. European Medicines Agency. Ozempic (semaglutide) — European Public Assessment Report and Product Information. Updated August 2026.
3. European Medicines Agency. Rybelsus (semaglutide) — European Public Assessment Report and Product Information. Updated April 2026.
4. U.S. Food and Drug Administration. FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated With Compounded Injectable Semaglutide Products.
5. U.S. Food and Drug Administration. FDA's Concerns With Unapproved GLP-1 Drugs Used for Weight Loss.
6. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002.

ALSO READ: A Complete Guide for Foreign Pharmacists to Obtain a Canadian License